Cbr3-flox Mouse
一般名
Cbr3-flox
製品ID
S-CKO-00807
背景情報
C57BL/6JCya
系統ID
CKOCMP-109857-Cbr3-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Cbr3-flox Mouse（カタログ番号S-CKO-00807）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Cbr3-flox
系統ID
CKOCMP-109857-Cbr3-B6J-VA
遺伝子名
製品ID
S-CKO-00807
遺伝子別名
1110001J05Rik
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conditional knockout
染色体
Chr 16
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000039620
NCBIトランスクリプトID
NM_173047
ターゲット領域
Exon 3
有効領域の大きさ
~1.6 kb
遺伝子研究の概要
Cbr3, also known as carbonyl reductase 3, is involved in various biological processes and diseases. Its single nucleotide polymorphism (V244M) has been linked to the risk of anthracycline-related cardiomyopathy, with the CBR3 V244M genotype status associated with changes in echocardiographic parameters suggestive of early anthracycline-related cardiomyopathy in breast cancer patients undergoing chemotherapy [5].
The long non-coding RNA CBR3-AS1, which is related to Cbr3, has been found to play oncogenic roles in multiple cancers. In gestational choriocarcinoma, it accelerates malignant proliferation by stabilizing SETD4 [1]. In osteosarcoma, it promotes stemness, EMT, and tumor growth through the miR-140-5p/DDX54-NUCKS1-mTOR signaling pathway [2]. In cervical cancer, high expression of CBR3-AS1 predicts poor prognosis and promotes cancer progression through the miR-3163/LASP1 pathway [4]. In lung adenocarcinoma, it potentiates Wnt/β-catenin signaling to regulate cell proliferation, migration, and invasion [6]. In colorectal cancer, it promotes stem-like properties and oxaliplatin resistance by sponging miR-145-5p [7]. In breast cancer, it regulates drug sensitivity as a competing endogenous RNA through the JNK1/MEK4-mediated MAPK signal pathway [8]. In ulcerative colitis, it promotes and enhances malignancy by targeting miRNA-145-5p/FN1 [3]. Additionally, allicin affects the immunoreactivity of osteosarcoma cells through the CBR3-AS1/miR-145-5p/GRP78 axis [9].
In conclusion, Cbr3 and its related lncRNA CBR3-AS1 are involved in multiple biological processes and play important roles in various diseases, especially in cancer progression and drug-related cardiotoxicity. Studies on these genes help to understand the mechanisms of disease occurrence and may provide new strategies for treatment.
References：
1. Zhang, Yajuan, Zhang, Hongxiu, Zhang, Xiaolei, Liu, Bin. 2022. CBR3-AS1 Accelerates the Malignant Proliferation of Gestational Choriocarcinoma Cells by Stabilizing SETD4. In Disease markers, 2022, 7155525. doi:10.1155/2022/7155525. https://pubmed.ncbi.nlm.nih.gov/35655916/
2. Yao, Weitao, Hou, Jingyu, Liu, Guoqing, Guo, Liangyu, Wang, Chuchu. 2022. LncRNA CBR3-AS1 promotes osteosarcoma progression through the network of miR-140-5p/DDX54-NUCKS1-mTOR signaling pathway. In Molecular therapy oncolytics, 25, 189-200. doi:10.1016/j.omto.2022.03.001. https://pubmed.ncbi.nlm.nih.gov/35592388/
3. Cao, Jingmei, Zhao, Qing, Jia, Qing, Li, Yiming. 2023. LncRNA-CBR3-AS1 promotes and enhances the malignancy of ulcerative colitis via targeting miRNA-145-5p/FN1. In Cellular and molecular biology (Noisy-le-Grand, France), 69, 181-186. doi:10.14715/cmb/2023.69.7.29. https://pubmed.ncbi.nlm.nih.gov/37715388/
4. Cai, Yipin, Huang, Yu, Zhang, Jie, Huang, Haiwei, Gao, Yu. . LncRNA CBR3-AS1 predicts a poor prognosis and promotes cervical cancer progression through the miR-3163/LASP1 pathway. In Neoplasma, 69, 1406-1417. doi:10.4149/neo_2022_220730N784. https://pubmed.ncbi.nlm.nih.gov/36591804/
5. Lang, Jennifer K, Karthikeyan, Badri, Quiñones-Lombraña, Adolfo, Blanco, Javier G, O'Connor, Tracey. 2021. CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin. In Cardio-oncology (London, England), 7, 17. doi:10.1186/s40959-021-00103-0. https://pubmed.ncbi.nlm.nih.gov/33975650/
6. Hou, Min, Wu, Nannan, Yao, Lili. 2021. LncRNA CBR3-AS1 potentiates Wnt/β-catenin signaling to regulate lung adenocarcinoma cells proliferation, migration and invasion. In Cancer cell international, 21, 36. doi:10.1186/s12935-020-01685-y. https://pubmed.ncbi.nlm.nih.gov/33422081/
7. Xie, Liangbao, Cui, Guangfei, Li, Tao. 2022. Long Noncoding RNA CBR3-AS1 Promotes Stem-like Properties and Oxaliplatin Resistance of Colorectal Cancer by Sponging miR-145-5p. In Journal of oncology, 2022, 2260211. doi:10.1155/2022/2260211. https://pubmed.ncbi.nlm.nih.gov/35466320/
8. Zhang, Ming, Wang, Yan, Jiang, Longyang, Wei, Minjie, Zhao, Lin. 2021. LncRNA CBR3-AS1 regulates of breast cancer drug sensitivity as a competing endogenous RNA through the JNK1/MEK4-mediated MAPK signal pathway. In Journal of experimental & clinical cancer research : CR, 40, 41. doi:10.1186/s13046-021-01844-7. https://pubmed.ncbi.nlm.nih.gov/33494806/
9. Xie, Wenpeng, Ma, Fengjun, Dou, Luming, Zhang, Zhimeng, Zhang, Yongkui. 2024. Allicin affects immunoreactivity of osteosarcoma cells through lncRNA CBR3-AS1. In Heliyon, 10, e31971. doi:10.1016/j.heliyon.2024.e31971. https://pubmed.ncbi.nlm.nih.gov/38947424/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。